ReviewCurrent opinion in microbiology2018
How bacteria control the CRISPR-Cas arsenal.
Review in Current opinion in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseases.Biosafety and health · 2025Review
- From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance-a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Role of phage therapy in acute gastroenteritis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Exploring pangenomic diversity and CRISPR-Cas evasion potential in jumbo phages: a comparative genomics study.Microbiology spectrum · 2024Article
- Exploiting the Specificity of CRISPR/Cas System for Nucleic Acids Amplification-Free Disease Diagnostics in the Point-of-Care.Chem & bio engineering · 2024Review
- CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.ACS infectious diseases · 2023Review
- Unveil the Secret of the Bacteria and Phage Arms Race.International journal of molecular sciences · 2023Review
- Evolutionary Dynamics between Phages and Bacteria as a Possible Approach for Designing Effective Phage Therapies against Antibiotic-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2022Review
- CRISPR-Cas Systems-Based Bacterial Detection: A Scoping Review.Diagnostics (Basel, Switzerland) · 2022Article
- Characterization of CRISPR-Cas systems inMicrobial genomics · 2022Article
- Double nicking by RNA-directed Cascade-nCas3 for high-efficiency large-scale genome engineering.Open biology · 2022Article
- Digging into the lesser-known aspects of CRISPR biology.International microbiology : the official journal of the Spanish Society for Microbiology · 2021Review
- Advances in biosensing: The CRISPR/Cas system as a new powerful tool for the detection of nucleic acids.Journal of pharmaceutical and biomedical analysis · 2021Review
- Delivering on the promise of gene editing for cystic fibrosis.Genes & diseases · 2019Review
- Natural tuning of restriction endonuclease synthesis by cluster of rare arginine codons.Scientific reports · 2019Article
- The CRISPR conundrum: evolve and maybe die, or survive and risk stagnation.Microbial cell (Graz, Austria) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
CRISPR-Cas systems are adaptive immune systems that protect their hosts from predation by bacteriophages (phages) and parasitism by other mobile genetic elements (MGEs). Given the potent nuclease activity of CRISPR effectors, these enzymes must be carefully regulated to minimize toxicity and maximize anti-phage immunity. While attention has been given to the transcriptional regulation of these systems (reviewed in [1]), less consideration has been given to the crucial post-translational processes that govern enzyme activation and inactivation. Here, we review recent findings that describe how Cas nucleases are controlled in diverse systems to provide a robust anti-viral response while limiting auto-immunity. We also draw comparisons to a distinct bacterial immune system, restriction-modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.